NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:46 am EST
Share
NKMAX CO., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 13,648.6 million compared to KRW 3,825.57 million a year ago. Basic loss per share from continuing operations was KRW 347 compared to KRW 110 a year ago. Diluted loss per share from continuing operations was KRW 347 compared to KRW 110 a year ago. Basic loss per share was KRW 347 compared to KRW 110 a year ago.
For the nine months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 43,711.31 million compared to KRW 33,342.25 million a year ago. Basic loss per share from continuing operations was KRW 1,114 compared to KRW 956 a year ago. Diluted loss per share from continuing operations was KRW 1,114 compared to KRW 956 a year ago. Basic loss per share was KRW 1,114 compared to KRW 956 a year ago.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 
